keyword
https://read.qxmd.com/read/31933161/uric-acid-in-ckd-has-the-jury-come-to-the-verdict
#1
REVIEW
Barbara Bonino, Giovanna Leoncini, Elisa Russo, Roberto Pontremoli, Francesca Viazzi
Epidemiological studies show that hyperuricemia independently predicts the development of chronic kidney disease (CKD) in individuals with normal kidney function both in the general population and in subjects with diabetes. As a matter of fact, an unfavorable role of uric acid may somewhat be harder to identify in the context of multiple risk factors and pathogenetic mechanisms typical of overt CKD such as proteinuria and high blood pressure. Although the discrepancy in clinical results could mean that urate lowering treatment does not provide a constant benefit in all patients with hyperuricemia and CKD, we believe that the inconsistency in the results from available meta-analysis is mainly due to inadequate sample size, short follow-up times and heterogeneity in study design characterizing the randomized controlled trials included in the analyses...
January 13, 2020: Journal of Nephrology
https://read.qxmd.com/read/31729647/intensive-uric-acid-lowering-therapy-in-ckd-patients-the-protocol-for-a-randomized-controlled-trial
#2
Masato Kasahara, Yoshihiro Kuwabara, Toshiki Moriyama, Kazuaki Tanabe, Noriko Satoh-Asahara, Tomohiro Katsuya, Shinya Hiramitsu, Hidetaka Shimada, Tosiya Sato, Yoshihiko Saito, Takahiko Nakagawa
BACKGROUND: Hyperuricemia would be a risk factor for the development/progression of CKD. However, several studies showed U-shape association between serum uric acid level and renal impairment, suggesting that hypouricemia was rather associated with renal dysfunction. Perhaps, there is the optimal target level of serum UA for renal function. METHODS: The Target-UA study is a multicenter randomized controlled trial. Eligible CKD patients (eGFR ≥ 30, < 60 mL/min/1...
November 15, 2019: Clinical and Experimental Nephrology
https://read.qxmd.com/read/31335677/effects-of-febuxostat-on-renal-function-in-patients-with-chronic-kidney-disease-a-systematic-review-and-meta-analysis
#3
Tsu-Chen Lin, Lie Yee Hung, Ying-Chun Chen, Wei-Cheng Lo, Chun Hung Lin, Ka-Wai Tam, Mei-Yi Wu
BACKGROUND/OBJECTIVE: Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia. METHODS: We have systematically searched for randomized controlled trials assessing the efficacy and safety of febuxostat versus control in CKD patients with hyperuricemia through MEDLINE, PubMed, EMBASE, and Cochrane databases...
July 2019: Medicine (Baltimore)
https://read.qxmd.com/read/31206563/urate-lowering-agents-for-asymptomatic-hyperuricemia-in-stage-3-4-chronic-kidney-disease-controversial-role-of-kidney-function
#4
Hee Jung Jeon, Jieun Oh, Dong Ho Shin
Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD). Although hyperuricemia is a risk factor for CKD progression, the causal role of uric acid remains controversial in patients with CKD and asymptomatic hyperuricemia. This study included 588 patients with stage 3-4 CKD and asymptomatic hyperuricemia. Using propensity score matching, 165 pairs treated and untreated with pharmacologic urate-lowering therapy were matched...
2019: PloS One
https://read.qxmd.com/read/30708071/beneficial-effects-of-sglt2-inhibitors-on-fatty-liver-in-type-2-diabetes-a-common-comorbidity-associated-with-severe-complications
#5
REVIEW
A J Scheen
Patients with type 2 diabetes mellitus (T2DM) are exposed to non-alcoholic fatty liver disease (NAFLD), a comorbidity associated with cardiovascular disease and chronic kidney disease, and which may progress to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Sodium-glucose cotransporter type-2 (SGLT2) inhibitors are glucose-lowering agents that improve glucose control while promoting weight loss and lowering serum uric acid levels. These agents may exert cardiovascular and renal protection in T2DM patients with established cardiovascular disease...
June 2019: Diabetes & Metabolism
https://read.qxmd.com/read/30642279/serum-uric-acid-and-cardiovascular-mortality-in-chronic-kidney-disease-a-meta-analysis
#6
Qimei Luo, Xi Xia, Bin Li, Zhenchuan Lin, Xueqing Yu, Fengxian Huang
BACKGROUND: Conflicting results have been reported from studies evaluating serum uric acid (SUA) levels as an independent risk factor for cardiovascular mortality in patients with chronic kidney disease (CKD). METHODS: We systematically searched MEDLINE, Web of Science, and bibliographies of retrieved articles to identify studies reporting on the association between SUA levels and cardiovascular mortality in patients with CKD. Random-effects models were used to calculate the pooled hazard ratios (HR) and corresponding 95% confidence intervals (CI)...
January 14, 2019: BMC Nephrology
https://read.qxmd.com/read/30561114/effects-of-probiotic-supplements-on-the-progression-of-chronic-kidney-disease-a-meta-analysis
#7
Sibei Tao, Siying Tao, Yiming Cheng, Jing Liu, Liang Ma, Ping Fu
BACKGROUND: Chronic kidney disease (CKD) is a worldwide public health problem. Although accumulated data suggested that probiotic supplements played roles in CKD, the results remained controversial. Here, we performed a meta-analysis to assess the effects of probiotic supplements on the CKD progression. METHODS: A systematic search was conducted through the PubMed, Embase and Cochrane databases until September 2018. Randomized controlled trials with control receiving placebo, evaluating the effects of probiotic supplements on CKD were included...
December 18, 2018: Nephrology
https://read.qxmd.com/read/30186411/efficacy-and-safety-of-febuxostat-for-treating-hyperuricemia-in-patients-with-chronic-kidney-disease-and-in-renal-transplant-recipients-a-systematic-review-and-meta-analysis
#8
Xuzhong Liu, Kun Liu, Qing Sun, Yunyan Wang, Junsong Meng, Zongyuan Xu, Zhaofei Shi
Febuxostat is potent and well-tolerated in the management of chronic gout. However, its clinical efficacy and safety in the treatment of hyperuricemia in patients with chronic kidney disease (CKD) and in renal transplant recipients have remained to be fully determined. The MEDLINE, EMBASE and Cochrane Library databases were searched for relevant articles. Data were extracted and pooled results were estimated from the standard mean difference (SMD) with 95% confidence intervals (95% CIs). The quality of the studies included was assessed, and their publication bias was examined...
September 2018: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/29761242/safety-and-efficacy-of-benzbromarone-and-febuxostat-in-hyperuricemia-patients-with-chronic-kidney-disease-a-prospective-pilot-study
#9
Haibo Yu, Xinying Liu, Yaxiang Song, Jiafen Cheng, Hui Bao, Ling Qin, Xuan Zhou, Ling Wang, Ai Peng
BACKGROUND: To compare the safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with estimated glomerular filtration rate (eGFR) 20-60 mL/min/1.73 m2 . METHODS: This study was a single-centered, parallel-grouped, randomized clinical trial (RCT). We randomly assigned hyperuricemia participants with eGFR 20-60 mL/min/1.73 m2 into benzbromarone and febuxostat treatment group. Drugs were adjusted by titration from small doses. RESULTS: Seventy-three eligible participants enrolled, 66 subjects (33 in each group) were included finally for analysis...
May 14, 2018: Clinical and Experimental Nephrology
https://read.qxmd.com/read/29619870/effects-of-uric-acid-lowering-therapy-on-the-progression-of-chronic-kidney-disease-a-systematic-review-and-meta-analysis
#10
REVIEW
Xuemei Liu, Tingting Zhai, Ruixia Ma, Congjuan Luo, Huifang Wang, Liqiu Liu
OBJECTIVES: Whether uric acid levels were associated with the progression of chronic kidney disease (CKD) remained controversial. This meta-analysis was aimed to assess the effect of lowering serum uric acid therapy on the progression of CKD to clarify the role of uric acid in the progression of CKD indirectly. METHODS: Pubmed, Embase, the Cochrane library, CBM were searched for randomized controlled trials (RCTs) that assessed the efficiency of lowering serum uric acid therapy on the progression of CKD without language restriction...
November 2018: Renal Failure
https://read.qxmd.com/read/29497863/does-altered-uric-acid-metabolism-contribute-to-diabetic-kidney-disease-pathophysiology
#11
REVIEW
Ambreen Gul, Philip Zager
PURPOSE OF REVIEW: Multiple experimental and clinical studies have identified pathways by which uric acid may facilitate the development and progression of chronic kidney disease (CKD) in people with diabetes. However, it remains uncertain if the association of uric acid with CKD represents a pathogenic effect or merely reflects renal impairment. RECENT FINDINGS: In contrast to many published reports, a recent Mendelian randomization study did not identify a causal link between uric acid and CKD in people with type 1 diabetes...
March 1, 2018: Current Diabetes Reports
https://read.qxmd.com/read/29095953/effects-of-uric-acid-lowering-therapy-in-patients-with-chronic-kidney-disease-a-meta-analysis
#12
Xiaole Su, Boyang Xu, Bingjuan Yan, Xi Qiao, Lihua Wang
BACKGROUND AND OBJECTIVES: The effects of uric acid-lowering therapy in patients with chronic kidney disease (CKD) remain uncertain. Therefore, we undertook a systematic review and meta-analysis to investigate the effects of uric acid-lowering agents on major clinical outcomes of CKD. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: According to the pre-specified protocol that was registered with PROSPERO (No. CRD42016038030), we searched systematically in MEDLINE, EMBASE, and the Cochrane Library for trials up to February 2016...
2017: PloS One
https://read.qxmd.com/read/28904879/renoprotective-effects-of-febuxostat-compared-with-allopurinol-in-patients-with-hyperuricemia-a-systematic-review-and-meta-analysis
#13
Sollip Kim, Hyun-Jung Kim, Hyeong-Sik Ahn, Se Won Oh, Kum Hyun Han, Tae-Hyun Um, Chong-Rae Cho, Sang Youb Han
BACKGROUND: Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can be alternatively used for patients who are intolerable to allopurinol. We aimed to determine renoprotective effect and urate-lowering effect between the two drugs. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials to assess the effects of febuxostat compared to allopurinol in patients with hyperuricemia...
September 2017: Kidney Research and Clinical Practice
https://read.qxmd.com/read/28846182/effects-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-on-serum-uric-acid-level-a-meta-analysis-of-randomized-controlled-trials
#14
Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen
The aim of this study was to describe the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM). PubMed, CENTRAL, EMBASE and ClinicalTrials.gov were searched for randomized controlled trials of SGLT2 inhibitors in patients with T2DM up to May 20, 2017. A total of 62 studies, comprising 34 941 patients, were included. Any of the SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, tofogliflozin, luseogliflozin or ipragliflozin) significantly decreased SUA levels compared with control (total weighted mean difference [WMD] -37...
February 2018: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/28045962/association-of-tsh-elevation-with-all-cause-mortality-in-elderly-patients-with-chronic-kidney-disease
#15
Mei-Hsing Chuang, Kuo-Meng Liao, Yao-Min Hung, Yi-Chang Chou, Pesus Chou
Chronic kidney disease (CKD) is a widespread condition in the global population and is more common in the elderly. Thyroid-stimulating hormone (TSH) level increases with aging, and hypothyroidism is highly prevalent in CKD patients. However, the relationship between low thyroid function and mortality in CKD patients is unclear. Therefore, we conducted a retrospective cohort study to examine the relationship between TSH elevation and all-cause mortality in elderly patients with CKD. This retrospective cohort study included individuals ≥65 years old with CKD (n = 23,786) in Taipei City...
2017: PloS One
https://read.qxmd.com/read/27903994/synbiotic-supplementations-for-azotemia-in-patients-with-chronic-kidney-disease-a-randomized-controlled-trial
#16
RANDOMIZED CONTROLLED TRIAL
Hamideh Dehghani, Fatemeh Heidari, Hassan Mozaffari-Khosravi, Nader Nouri-Majelan, Ali Dehghani
INTRODUCTION: Chronic kidney disease (CKD) is a progressive and irreversible impairment of kidney function; if it progresses to the end-stage of CKD, dialysis or kidney transplant is needed. In general, there are no definitive treatment to slow the progression of CKD. This study aimed to determine the effect of synbiotic supplementations on azotemia in patients with CKD. MATERIALS AND METHODS: A randomized controlled trial was conducted on 66 patients with CKD (stages 3 and 4)...
November 2016: Iranian Journal of Kidney Diseases
https://read.qxmd.com/read/27696189/hyperuricemia-hypertension-and-chronic-kidney-disease-an-emerging-association
#17
REVIEW
Samir G Mallat, Sahar Al Kattar, Bassem Y Tanios, Abdo Jurjus
Uric acid is a product of purine metabolism and has been linked to gout and kidney calculi. Chronic kidney disease (CKD) and hypertension (HTN) are two major public health problems, and both are associated with increased risk of cardiovascular events. Emerging evidence suggests a pathogenic role of hyperuricemia in the development of HTN and CKD, in addition to progression of CKD, by inducing renal inflammation, endothelial dysfunction, and activation of the renin-angiotensin system. In addition, several epidemiological studies have linked hyperuricemia with an increased risk of HTN and CKD...
October 2016: Current Hypertension Reports
https://read.qxmd.com/read/27506740/serum-uric-acid-and-mortality-in-chronic-kidney-disease-a-systematic-review-and-meta-analysis
#18
REVIEW
Xi Xia, Qimei Luo, Bin Li, Zhenchuan Lin, Xueqing Yu, Fengxian Huang
BACKGROUND: Studies have shown inconsistent results about the association between serum uric acid levels and mortality in patients with chronic kidney disease (CKD). METHODS: A systematic literature search in MEDLINE, Web of Science and bibliographies of retrieved articles was performed to identify studies investigating the association between serum uric acid and mortality in patients with CKD. Pooled hazard ratios (HR) and corresponding 95% confidence intervals (CIs) were calculated using random-effects models...
September 2016: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/27269247/the-budget-impact-of-increased-use-of-febuxostat-in-the-management-of-gout-a-us-health-plan-managed-care-pharmacy-and-medical-costs-perspective
#19
Lee J Smolen, James C Gahn, Ghaith Mitri, Aki Shiozawa
PURPOSE: Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA). The study estimates pharmacy and medical cost budgetary impacts of wider adoption by US payers of febuxostat, a urate-lowering therapy (ULT) for the treatment of gout. METHODS: A US payer-perspective budget impact model followed ULT patients from a 1,000,000-member plan over 3 years. The current market share scenario, febuxostat (6%) and ULT allopurinol (94%), was compared with an 18% febuxostat market share...
July 2016: Clinical Therapeutics
https://read.qxmd.com/read/26535593/febuxostat-in-the-management-of-gout-a-cost-effectiveness-analysis
#20
COMPARATIVE STUDY
Lee J Smolen, James C Gahn, Ghaith Mitri, Aki Shiozawa
OBJECTIVE: To determine the cost-effectiveness of febuxostat vs allopurinol for the management of gout. METHODS: A stochastic microsimulation cost-effectiveness model with a US private-payer perspective and 5-year time horizon was developed. Model flow based on guideline and real-world treatment paradigms incorporated gout flare, serum uric acid (sUA) testing, treatment titration, discontinuation, and adverse events, chronic kidney disease (CKD) incidence and progression, and type 2 diabetes mellitus (T2DM) incidence...
2016: Journal of Medical Economics
keyword
keyword
101042
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"